[Form 4] Akero Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Akero Therapeutics, Inc. (AKRO) – Form 4 insider transaction

Chief Development Officer Catriona Yale reported a single non-derivative transaction on 18 June 2025. The filing shows the automatic sale of 1,633 common shares at a weighted-average price of $54.84 (individual trades ranged from $54.33 to $54.84). The transaction was coded “S” and was executed under the company’s sell-to-cover policy to satisfy tax-withholding obligations arising from the vesting of restricted stock units. According to the footnotes, the sales were automatic and not at the officer’s discretion.

Following the transaction Ms. Yale continues to own 90,598 common shares directly. No derivative security activity was reported in Table II, and no additional transactions were disclosed.

The filing is a routine Section 16 disclosure; no earnings data, options exercises, or new awards were included.

Positive

• Officer retains 90,598 shares after the transaction, demonstrating continued equity exposure.
• Sale was mandated by a pre-arranged sell-to-cover policy, reducing concerns about discretionary insider selling.

Negative

• Form 4 shows 1,633 shares sold by the Chief Development Officer, which some investors may view as insider selling despite its procedural nature.

Insights

Corporate Governance Expert

TL;DR: Small, policy-driven insider sale; neutral governance impact.

The Form 4 documents a modest disposition (1,633 shares) by Akero’s CDO purely to cover taxes on RSU vesting. Because the issuer’s pre-arranged “sell-to-cover” policy mandated the transaction, it does not signal a discretionary change in insider sentiment. The executive’s post-sale stake of 90,598 shares indicates continued alignment with shareholders. With no derivative activity and no indication of strategic intent, I view the governance and market impact as immaterial.

Sell-Side Biotechnology Analyst

TL;DR: De-minimis insider sale; unlikely to affect AKRO valuation.

The 1,633-share sale equates to a very small fraction of Ms. Yale’s reported holdings and was executed under a mechanical sell-to-cover program. No purchase or larger sale patterns are evident, and the officer retains a substantial 90k-plus share position. Absent additional insider activity or operational news, I classify the event as non-impactful to the investment thesis or near-term trading dynamics.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yale Catriona

(Last) (First) (Middle)

601 GATEWAY BOULEVARD

SUITE 350

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Akero Therapeutics, Inc. [ AKRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2025		S(1)		1,633	D	$54.84(2)	90,598	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person.

2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.33 to $54.84, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

	/s/ Jonathan Young, Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Akero Therapeutics (AKRO) shares did the insider sell?

1,633 common shares were sold on 18 June 2025.

At what price were the AKRO shares sold?

The weighted-average sale price was $54.84, with trades ranging from $54.33 to $54.84.

Why did the Akero insider sell shares?

The sale was a sell-to-cover transaction to pay tax withholding on vested restricted stock units.

How many AKRO shares does the insider now own?

After the sale, the officer directly owns 90,598 shares of common stock.

Was any derivative security activity reported in the Form 4?

No. Table II shows no derivative securities acquired or disposed of.